Advances in immune neoadjuvant/adjuvant therapy-related adverse events of non-small cell lung cancer.
Qingchun ZhaoChao LiuHongyu LiuJun ChenPublished in: Asia-Pacific journal of clinical oncology (2020)
Lung cancer has been the leading cause of cancer-related death for decades and years. For the patients with early stage non-small cell lung cancer, surgical resection is the mainstay of therapy. Treatment before and after surgery, such as chemotherapy, can bring benefit to these patients, improving the 5 years survival rate by 5% approximately. Recently, the advent of immunotherapy significantly improved prognosis for the patient with lung cancer. Programmed death 1 and its ligand have become a powerful treatment option for lung cancer. In this review, we will discuss the role immunotherapy played in preoperative neoadjuvant and postoperative adjuvant treatment in lung cancer.
Keyphrases
- early stage
- rectal cancer
- locally advanced
- end stage renal disease
- patients undergoing
- squamous cell carcinoma
- chronic kidney disease
- ejection fraction
- stem cells
- mesenchymal stem cells
- prognostic factors
- neoadjuvant chemotherapy
- case report
- radiation therapy
- combination therapy
- smoking cessation
- sentinel lymph node